A. Sinclair Dunlop, Director at Apellis Pharmaceuticals, Inc. (APLS), sold 305,746 shares at $50.00 ($16.1M) on 2021-05-19, disclosed to the SEC on 2021-05-20.
Open-market sale of $16.1M APLS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $51.66 | 64,179 | $3.3M | 20.6% |
| 2 | $51.66 | 64,179 | $3.3M | 20.6% |
| 3 | $52.01 | 1,200 | $62K | 0.4% |
| 4 | $52.63 | 14,216 | $748K | 4.7% |
| 5 | $52.63 | 14,216 | $748K | 4.7% |
| 6 | $53.50 | 10,388 |
| $556K |
| 3.5% |
| 7 | $53.78 | 36,387 | $2.0M | 12.2% |
| 8 | $53.78 | 36,387 | $2.0M | 12.2% |
| 9 | $54.02 | 800 | $43K | 0.3% |
| 10 | $54.57 | 22,318 | $1.2M | 7.6% |
| 11 | $54.57 | 22,318 | $1.2M | 7.6% |
| 12 | $50.00 | 7,612 | $381K | 2.4% |
| 13 | $48.10 | 5,773 | $278K | 1.7% |
| 14 | $48.10 | 5,773 | $278K | 1.7% |
| Total | $52.57 avg | 305,746 | $16.1M | 100% |
| Filing → |
| APLS | SELL | 2025-09-19 | $1.4M | — | Filing → |
| APLS | SELL | 2024-09-17 | $2.7M | — | Filing → |
| APLS | SELL | 2024-06-21 | $2.9M | — | Filing → |